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Introduction {#sec001}
============

Colorectal cancer (CRC) is the third most common malignancy and the fourth leading cause of cancer-related death in the world with more than half million deaths every year \[[@pone.0200735.ref001]--[@pone.0200735.ref003]\]. Recent advances in our understanding of CRC epigenetic aberration have led to the identification of potential clinical biomarkers for prognostic, diagnostic, and therapeutic monitoring of CRC \[[@pone.0200735.ref003]\]. Early detection of colon cancer through screening and removal of adenomatous polyps prevents cancerous transformation and lowers the incidence and mortality rates \[[@pone.0200735.ref004]\]. One of the main process causing the initiation of CRC and transformation of benign polyps to malignant tumors is the accumulation of a variety of genetic and epigenetic changes in colonic epithelium \[[@pone.0200735.ref003], [@pone.0200735.ref005]\].

Although colonoscopic screening remains the gold standard for CRC screening, this procedure is invasive and expensive, and suffers from poor patient compliance \[[@pone.0200735.ref006]\]. Hence, there is remarkable interest in the development of accurate noninvasive screening tests, among which stool-based tests (*e*.*g*. stool DNA analysis) have been particularly the subject of extensive research. Stool DNA test, provides several advantages over colonoscopy, such as ease of performance, low risk and its low cost \[[@pone.0200735.ref007]\]. Stool DNA test detects aberrant methylation and mutation in DNA released from cells that are constantly shed from cancerous or pre-cancerous lesions \[[@pone.0200735.ref008]\]. Previous studies have identified a set of DNA methylation biomarkers isolated from patients\' stool as a user-friendly and cost-effective procedure for noninvasive screening and early detection of cancer with a high analytical sensitivity and stability superior to the guaiac-based fecal occult blood tests (g-FOBTs) \[[@pone.0200735.ref009]--[@pone.0200735.ref012]\]. Numerous tumor-related hypermethylated genes in the stool of CRC patients have been introduced with different sensitivity and specificity values for CRC \[[@pone.0200735.ref013]\] and a relatively unclear diagnostic performance in cancer.

Based on the above-mentioned points, this meta-analysis was conducted to assess the diagnostic performance of individual DNA hypermethylation genes in stool samples. We also aimed to find the best single genes for the diagnosis of colorectal cancerous and precancerous lesions.

Materials and methods {#sec002}
=====================

Literature search strategy {#sec003}
--------------------------

The meta-analysis was performed in accordance with the PRISMA 2009 guidelines \[[@pone.0200735.ref014]\]. We searched MEDLINE, Web of Science, Scopus and Google Scholar international databases until May 1, 2016. The keywords employed for literature retrieval were (Methylation/ Methylated/ Hypermethylation/ Hypermethylated) AND (Colorectal/ Colon/ Rectal/ \"large intestine\") AND (Stool/ Feces/ Fecal) AND (Sensitivity/ Specificity) AND (Tumor/ Cancer/ Polyp/ Carcinoma/ Adenocarcinoma/ Neoplas\*/ Adenom\*) AND NOT (Rat/ Mice/ Mouse). We contacted authors to obtain additional information when necessary.

Inclusion and exclusion criteria {#sec004}
--------------------------------

Two reviewers (M. A. and Y. M.) independently assessed all identified publications to determine their eligibility for inclusion in the study. Studies meeting the following criteria were included in the study: (1) employed colonofibroscopic or surgical pathology examination as the reference standard; (2) inclusion of a control group consisting of normal healthy individuals; (3) stool collection before any tumor removal and polypectomy; (4) all included studies used stool DNA hypermethylation tests as CRC screening tool; (5) provision of sufficient data for 2 × 2 table construction for each gene separately; (6) original articles; (7) full-length article published in English. Exclusion criteria were: (1) diagnoses of secondary or metastatic instead of primary colon cancer; (2) chronic inflammatory diseases mimicking malignancy (such as inflammatory bowel disease); (3) duplicate publication; (4) trials lacking appropriate informed consent; (5) studies without control or normal group; (6) studies with same population.

Study selection and data extraction {#sec005}
-----------------------------------

All potential studies were reviewed thoroughly by 2 independent reviewers (M. A. and Y. M.) using a standardized form ([S1 Table](#pone.0200735.s004){ref-type="supplementary-material"}). Any disagreement was resolved by discussion until consensus was reached. The reviewers were not blind to the journal and author names, author affiliations, or year of publication, as this procedure has been shown to be unnecessary. In this meta-analysis, 2 × 2 tables were constructed from each gene in each cancer category in all studies for the true-positive (TP), false-negative (FN), and true-negative (TN) and false-positive (FP) values. All essential data and relevant information, including the name of the first author, year of publication, sample size, study design, subject demographics, pathology or colonoscopy reports of participants, targeted genes, and lab DNA methylation detection method of targeted genes and country of study population were extracted from the included studies.

Quality assessment {#sec006}
------------------

The Revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool was utilized for quality assessment for the included studies \[[@pone.0200735.ref015]\], which has been demonstrated to be efficient for quality assessment of diagnostic accuracy studies. This tool consists of 4 key domains that cover patient selection, index tests, reference standard, and flow of patients through the study and timing of the index tests and reference standard (flow and timing). The quality assessment was also performed by the independent reviewers and a third reviewer was consulted for any uncertainties. The quality of each item was characterized as low, high, or unclear.

Statistical analysis {#sec007}
--------------------

The outcomes of the meta-analysis were the diagnostic performance, denoted as sensitivity, specificity, the positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) of single-gene tests. The summary receiver operating characteristic curve (SROC) displays the trade-off between sensitivity and specificity and represents a global summary of test performance. The PLR represents the value by which the odds of the disease increase when a test is positive, whereas the NLR shows the value by which the odds of the disease decrease when a test is negative \[[@pone.0200735.ref016]\].

Because random error and clinical or methodological heterogeneity can affect study results, heterogeneity among the studies was assessed by the Cochran Q and the I^2^ statistic. For the Q statistic, P \< 0.10 was considered statistically significant for heterogeneity. For the I^2^ statistic, which indicates the percentage of the observed between-study variability due to heterogeneity rather than chance, the following ranges were used: no heterogeneity (I^2^  =  0%--25%), moderate heterogeneity (I^2^  =  25%--50%), large heterogeneity (I^2^  =  50%--75%), and extreme heterogeneity (I^2^  =  75%--100%). Q statistics (P \< 0.1) or I^2^ statistic (I^2^ \> 50%) were considered to indicate the existence heterogeneity between studies.

We pooled estimates for sensitivity, specificity, the PLR, NLR, DOR and SROC curve. We used the professional statistical software programs (Meta-DiSc 1.4, Ramón y Cajal Hospital in Madrid, Spain) \[[@pone.0200735.ref016]\]. All statistics were calculated and then combined using a random-effects model and 95%CI as effect measurements for our analysis.

In addition, publication bias was inspected using Egger Test to evaluate Funnel plots of the DOR against study standard error. Funnel plot was conducted using Metafor package in R software \[[@pone.0200735.ref017]\].

Results {#sec008}
=======

Study selection {#sec009}
---------------

Of the 469 articles initially identified, in the next stage of assessment 205 duplicate publications were removed. One hundred fifty three were excluded by title and abstract. The remaining 52 studies were fully reviewed, of which 14 were excluded for not precisely meeting all the inclusion criteria. After carefully reading the texts, meta-analysis was performed on the final sample of 38 studies ([Fig 1](#pone.0200735.g001){ref-type="fig"}).

![Flow diagram of study selection.](pone.0200735.g001){#pone.0200735.g001}

Sample characteristics {#sec010}
----------------------

The total number of participants in the studies was 4867, with the percentage of male patients and controls ranging from 26.6%-70% to 35%-75% and the percentage of female patients and controls from 30%-73.33% to 25%-65%. The patients and controls had a mean age of 61.60 ± 12.37 and 55.76 ± 12.5, respectively. Patients were classified into four categories including; CRC, total adenoma (TA, including advanced adenoma; AA and non-advanced adenoma; NAA), hyperplastic polyp (HP) and CRC plus adenoma (total patients; TP) named from 1 to 4, respectively. In TP category, hyperplastic polyps were not included since there is a scanty chance of malignancy. The numbers of patients in the four categories were 2005, 667, 154, and 2762 respectively. The total number of control groups were 1951. The sensitivity of a given assay for detecting CRC and polyps in stool samples varied across the studies; the ranges for sensitivity of categories 1 to 4, were 20%-94%, 0%-100%, 0%-50% and 0%100%, whereas their specificities were 77%-100%, 73%-100%, 73%-100% and 73%-100%, respectively. The population studied, targeted genes assessed, the targeted categories, the analysis methods to detect the hypermethylation of the targets genes and the sensitivity and specificity of each gene in a certain category of a given study until 2016 are shown in [Table 1](#pone.0200735.t001){ref-type="table"}. Studies were conducted on four continents: Europe (n = 12; 1 in France, 3 in Spain, 4 in Netherland, 1 in Germany, 2 in Austria, 1 in Belgium), Asia (n = 20; 15 in China, 2 in Iran, 2 in South Korea, 1 in Japan), and North America (n = 4; all in the USA) and one multi-center study.

10.1371/journal.pone.0200735.t001

###### Summary of basic characteristics and performance of studies included in meta-analysis.

![](pone.0200735.t001){#pone.0200735.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ref.                                Study country   Detection method     Sample type: Number   Target Gene(s)   Study Group   TP     FN     TN    FP   Sensitivity[\*](#t001fn002){ref-type="table-fn"} (%)   Specificity[\*](#t001fn002){ref-type="table-fn"} (%)
  ----------------------------------- --------------- -------------------- --------------------- ---------------- ------------- ------ ------ ----- ---- ------------------------------------------------------ ------------------------------------------------------
  Li, W.-h., et al.\                  China           MSP                  CRC: 89\              *SNCA*           CRC/N         62     27     30    0    70                                                     100
  (2015) \[[@pone.0200735.ref018]\]                                        Control: 30                                                                                                                          

  *FBN1*                              CRC/N           63                   26                    28               2             71     93                                                                       

  Xiao, W., et al.\                   China           MSP                  CRC: 87\              *NDRG4*          CRC/N         66     21     14    2    76                                                     89
  (2015) \[[@pone.0200735.ref019]\]                                        Control: 16                                                                                                                          

  Amiot, A., et al.\                  France          qMSP                 CRC, AA: 90\          *Wif-1*          CRC+ AA/N     17     73     155   2    19                                                     99
  (2014) \[[@pone.0200735.ref020]\]                                        Control: 157                                                                                                                         

  *ALX4*                              CRC+AA/N        10                   80                    155              2             11     99                                                                       

  *VIM*                               CRC+AA/N        29                   61                    157              0             33     100                                                                      

  He, C. G., et al.\                  China           MSP                  CRC: 61\              *p33(ING1b)*     CRC/N         45     16     19    1    74                                                     95
  (2014) \[[@pone.0200735.ref011]\]                                        AA: 27\                                                                                                                              
                                                                           Control: 20                                                                                                                          

  *p33(ING1b)*                        AA/N            17                   10                    19               1             63     95                                                                       

  Lu, H., et al.\                     China           MSP                  CRC: 56\              *SFRP2*          CRC/ N        32     24     36    4    57                                                     90
  (2014) \[[@pone.0200735.ref021]\]                                        Control: 40                                                                                                                          

  *GATA4*                             CRC/N           24                   32                    38               2             43     95                                                                       

  *GATA5*                             CRC/N           47                   9                     33               7             84     85                                                                       

  *NDRG4*                             CRC/N           16                   40                    39               1             28.5   97.5                                                                     

  *VIM*                               CRC/N           23                   33                    34               6             42     85                                                                       

  Xiao, Z., et al.\                   China           MS_HRM               CRC: 40\              *SFRP2*          CRC/N         35     5      52    5    87.5                                                   91
  (2014) \[[@pone.0200735.ref022]\]                                        AA: 36\                                                                                                                              
                                                                           Control: 57                                                                                                                          

  *VIM*                               CRC/N           22                   18                    53               4             55     93                                                                       

  *SFRP2*                             AA/N            20                   16                    52               5             56     91                                                                       

  *VIM*                               AA/N            30                   6                     53               4             83     93                                                                       

  Zhang, H., et al.\                  China           MSP                  CRC: 48\              *SFRP2*          CRC/N         27     21     30    0    56                                                     100
  (2014) \[[@pone.0200735.ref010]\]                                        AA: 15\                                                                                                                              
                                                                           NAA: 20\                                                                                                                             
                                                                           HP: 32\                                                                                                                              
                                                                           Control: 30                                                                                                                          

  *Wif-1*                             CRC/N           29                   19                    29               1             60     97                                                                       

  *SFRP2*                             AA/N            9                    6                     30               0             60     100                                                                      

  *Wif-1*                             AA/N            8                    7                     29               1             53     97                                                                       

  *SFRP2*                             NAA/N           8                    12                    30               0             40     100                                                                      

  *Wif-1*                             NAA/N           7                    13                    29               1             35     97                                                                       

  *SFRP2*                             HP/N            4                    28                    30               0             12.5   100                                                                      

  *Wif-1*                             HP/N            6                    26                    29               1             19     97                                                                       

  Carmona, F. J., et al.\             Spain           Pyrosequencing       CRC: 68\              *AGTR1*          CRC/N         14     54     37    2    21                                                     95
  (2013) \[[@pone.0200735.ref023]\]                                        Control: 39                                                                                                                          

  *WNT2*                              CRC/N           21                   31                    38               1             40     97                                                                       

  *SLIT2*                             CRC/N           37                   34                    35               2             52     95                                                                       

  *VIM*                               CRC/N           18                   15                    19               3             55     86                                                                       

  *SEPT9*                             CRC/N           7                    28                    26               0             20     100                                                                      

  Guo, Q., et al.\                    China           MSP                  CRC: 75\              *FBN1*           CRC/N         54     21     28    2    72                                                     93
  (2013) \[[@pone.0200735.ref013]\]                                        Control: 30                                                                                                                          

  Zhang, H., et al.\                  China           MSP                  CRC: 96\              *SPG20*          CRC/N         77     19     30    0    80                                                     100
  (2013) \[[@pone.0200735.ref024]\]                                        Control: 30                                                                                                                          

  Bosch, L. J., et al.\               Netherland      qMSP                 CRC: 65\              *PHACTR3*        CRC/N         40     25     97    4    61.5                                                   96
  (2012) \[[@pone.0200735.ref025]\]                                        AA: 19\                                                                                                                              
                                                                           Control: 101                                                                                                                         

  *PHACTR3*                           AA/N            6                    13                    97               4             31.5   96                                                                       

  Salehi, R., et al.\                 Iran            MSP                  CRC: 25\              *SFRP1*          CRC/N         13     12     23    2    52                                                     92
  (2012) \[[@pone.0200735.ref026]\]                                        Control: 25                                                                                                                          

  Zhang, J., et al.\                  China           MSP                  CRC: 60\              *TFPI2*          CRC/N         41     19     30    0    68                                                     100
  (2012) \[[@pone.0200735.ref012]\]                                        A: 20\                                                                                                                               
                                                                           Control: 30                                                                                                                          

  *TFPI2*                             A/N             7                    13                    30               0             35     100                                                                      

  Tang, D., et al.\                   China           MSP                  CRC: 169\             *SFRP2*          CRC/N         142    27     28    2    84                                                     93
  (2011) \[[@pone.0200735.ref027]\]                                        AA: 63\                                                                                                                              
                                                                           Control: 30                                                                                                                          

  *SFRP2*                             AA/N            29                   34                    28               2             46     93                                                                       

  Azuara, D., et al\                  Spain           MS-MCA               CRC: 38\              *RARB2*          CRC/N         11     23     13    0    32                                                     100
  (2010) \[[@pone.0200735.ref028]\]                                        A: 40\                                                                                                                               
                                                                           Control: 20                                                                                                                          

  *P16*                               CRC/N           9                    21                    13               0             30     100                                                                      

  *MGMT*                              CRC/N           9                    19                    15               0             32     100                                                                      

  *APC*                               CRC/N           9                    19                    15               0             32     100                                                                      

  *RARB2*                             A/N             7                    31                    15               0             18     100                                                                      

  *P16*                               A/N             6                    28                    15               0             18     100                                                                      

  *MGMT*                              A/N             3                    34                    15               0             8      100                                                                      

  *APC*                               A/N             9                    25                    15               0             26     100                                                                      

  Baek, Y. H., et al.\                South Korea     MSP                  CRC: 60\              *MLH1*           CRC/N         18     42     37    0    30                                                     100
  (2009) \[[@pone.0200735.ref029]\]                                        A: 52\                                                                                                                               
                                                                           Control: 37                                                                                                                          

  *MGMT*                              CRC/N           31                   29                    32               5             52     86                                                                       

  *VIM*                               CRC/N           23                   37                    37               0             38     100                                                                      

  *MLH1*                              A/N             6                    46                    37               0             11     100                                                                      

  *MGMT*                              A/N             19                   33                    32               5             36.5   86                                                                       

  *VIM*                               A/N             8                    44                    37               0             15     100                                                                      

  Chang, E., et al.\                  South Korea     MSP                  CRC: 30\              *ITGA4*          CRC/N         11     19     31    0    37                                                     100
  (2009) \[[@pone.0200735.ref030]\]                                        A: 25\                                                                                                                               
                                                                           Control: 31                                                                                                                          

  *SFRP2*                             CRC/N           18                   12                    31               0             60     100                                                                      

  *P16*                               CRC/N           12                   18                    30               1             40     97                                                                       

  *ITGA4*                             A/N             4                    21                    31               0             16     100                                                                      

  *SFRP2*                             A/N             11                   14                    31               0             44     100                                                                      

  *P16*                               A/N             6                    19                    30               1             24     97                                                                       

  Glöckner, S. C., et al.\            Netherland      qMSP                 CRC: 84\              *TFPI2*          CRC/N         67     17     76    11   80                                                     87
  (2009) \[[@pone.0200735.ref031]\]                                        A: 26\                                                                                                                               
                                                                           Control: 87                                                                                                                          

  *TFPI2*                             A/N             7                    19                    76               11            27     87                                                                       

  Hellebrekers, D. M., et al.\        Netherland      qMSP                 CRC: 75\              *GATA4*          CRC/N         44     31     66    9    59                                                     88
  (2009) \[[@pone.0200735.ref032]\]                                        Control: 75                                                                                                                          

  Mayor, R., et al.\                  Spain           MS-MCA               CRC: 30\              *EN1*            CRC/N         8      22     29    1    27                                                     97
  (2009) \[[@pone.0200735.ref033]\]                                        Control: 30                                                                                                                          

  Melotte, V., et al.\                Netherland      qMSP                 CRC: 75\              *NDRG4*          CRC/N         42     33     72    3    56                                                     96
  (2009) \[[@pone.0200735.ref034]\]                                        Control: 75                                                                                                                          

  Nagasaka, T., et al.\               Japan           Fluorescence Hi-SA   CRC: 84\              *RASSF2*         CRC/N         38     46     107   6    45                                                     95
  (2009) \[[@pone.0200735.ref035]\]                                        AA: 27\                                                                                                                              
                                                                           NAA: 29\                                                                                                                             
                                                                           HP: 12\                                                                                                                              
                                                                           Control: 113                                                                                                                         

  *SFRP2*                             CRC/N           53                   31                    104              9             63     92                                                                       

  *RASSF2*                            AA/N            6                    20                    107              6             22     95                                                                       

  *SFRP2*                             AA/N            10                   17                    104              9             37     92                                                                       

  *RASSF2*                            NAA/N           1                    28                    107              6             3.5    95                                                                       

  *SFRP2*                             NAA/N           8                    21                    104              9             28     92                                                                       

  *RASSF2*                            HP/N            6                    6                     107              6             50     95                                                                       

  *SFRP2*                             HP/N            6                    6                     104              9             50     92                                                                       

  Kim, M. S., et al.\                 Belgium         qMSP                 CRC: 89\              *OSMR*           CRC/N         35     54     92    4    39                                                     96
  (2009) \[[@pone.0200735.ref036]\]                                        A: 17\                                                                                                                               
                                                                           Control: 96                                                                                                                          

  *SFRP1*                             CRC/N           11                   9                     15               0             55     100                                                                      

  *B4GALT1*                           CRC/N           9                    7                     8                2             56     80                                                                       

  *OSMR*                              A/N             2                    14                    92               4             13     96                                                                       

  *SFRP1*                             A/N             5                    12                    15               0             29     100                                                                      

  Itzkowitz, S., et al.\              United States   MSP                  CRC: 22\              *VIM*            CRC/N         9      13     36    2    41                                                     95
  (2008) \[[@pone.0200735.ref037]\]                                        AA: 20\                                                                                                                              
                                                                           Control: 38                                                                                                                          

  *VIM*                               AA/N            9                    11                    36               2             45     95                                                                       

  Li, M., et al.\                     United States   Methyl-BEAMing       CRC: 42\              *VIM*            CRC/N         34     8      198   43   81                                                     82
  (2009) \[[@pone.0200735.ref038]\]                                        AA: 6\                                                                                                                               
                                                                           Control: 241                                                                                                                         

  *VIM*                               AA/N            6                    0                     198              43            100    82                                                                       

  Oberwalder, M., et al.\             Austria         Methyl Light         A: 13\                *SFRP2*          CRC/N         6      7      6     0    46                                                     100
  (2008) \[[@pone.0200735.ref039]\]                                        HP: 6\                                                                                                                               
                                                                           Control: 6                                                                                                                           

  *SFRP2*                             HP/N            2                    4                     6                0             33     100                                                                      

  Tang, D., et al.\                   China           MSP                  CRC: 39\              *SFRP1*          CRC/N         35     4      18    2    90                                                     90
  (2008) \[[@pone.0200735.ref040]\]                                        AA: 19\                                                                                                                              
                                                                           NAA: 15\                                                                                                                             
                                                                           HP: 17\                                                                                                                              
                                                                           Control: 20                                                                                                                          

  *SFRP2*                             CRC/N           32                   7                     19               1             82     95                                                                       

  *SFRP1*                             AA/N            14                   5                     18               2             74     90                                                                       

  *SFRP2*                             AA/N            13                   6                     19               1             68     95                                                                       

  *SFRP1*                             NAA/N           8                    7                     18               2             53     90                                                                       

  *SFRP2*                             NAA/N           6                    9                     19               1             40     95                                                                       

  *SFRP1*                             HP/N            6                    11                    18               2             35     90                                                                       

  *SFRP2*                             HP/N            5                    12                    19               1             29     95                                                                       

  Wang, D.-R. and D. Tang\            China           Methyl Light         CRC: 69\              *SFRP2*          CRC/N         60     9      28    2    87                                                     94
  (2008) \[[@pone.0200735.ref041]\]                                        AA: 34\                                                                                                                              
                                                                           HP 26\                                                                                                                               
                                                                           Control: 30                                                                                                                          

  *SFRP2*                             AA/N            21                   13                    28               2             62     94                                                                       

  *SFRP2*                             HP/N            11                   15                    28               2             42     94                                                                       

  Abbaszadegan, M. R., et al.\        Iran            MSP                  CRC: 25\              *P16*            CRC/N         5      20     20    0    20                                                     100
  (2007) \[[@pone.0200735.ref042]\]                                        Control: 20                                                                                                                          

  Huang, Z.-H., et al.\               China           MSP                  CRC: 52\              *SFRP2*          CRC/N         49     3      23    1    94                                                     96
  (2007) \[[@pone.0200735.ref043]\]                                        A: 21\                                                                                                                               
                                                                           HP: 8\                                                                                                                               
                                                                           Control: 24                                                                                                                          

  *HPP1*                              CRC/N           37                   15                    24               0             71     100                                                                      

  *MGMT*                              CRC/N           25                   27                    24               0             48     100                                                                      

  *SFRP2*                             A/N             11                   10                    23               1             52     96                                                                       

  *HPP1*                              A/N             12                   9                     24               0             57     100                                                                      

  *MGMT*                              A/N             6                    15                    24               0             29     100                                                                      

  *SFRP2*                             HP/N            3                    5                     23               1             37.5   96                                                                       

  *HPP1*                              HP/N            2                    6                     24               0             25     100                                                                      

  *MGMT*                              HP/N            1                    7                     24               0             12.5   100                                                                      

  *SFRP2*                             HP/N            3                    5                     23               1             37.5   96                                                                       

  *HPP1*                              HP/N            2                    6                     24               0             25     100                                                                      

  *MGMT*                              HP/N            1                    7                     24               0             12.5   100                                                                      

  Itzkowitz, S. H., et al.\           7 Center        MSP                  CRC: 40\              *VIM*            CRC/N         29     11     106   16   72.5                                                   87
  (2007) \[[@pone.0200735.ref044]\]                                        Control: 122                                                                                                                         

  *HLTF*                              CRC/N           15                   25                    113              9             37.5   93                                                                       

  Leung, W. K., et al.\               China           MSP                  CRC: 20\              *SFRP2*          CRC/N         6      14     28    2    30                                                     93
  (2007) \[[@pone.0200735.ref045]\]                                        A: 25\                                                                                                                               
                                                                           HP: 5\                                                                                                                               
                                                                           Control: 30                                                                                                                          

  *MGMT*                              CRC/N           4                    16                    30               0             20     100                                                                      

  *MLH1*                              CRC/N           4                    16                    30               0             20     100                                                                      

  *HLTF*                              CRC/N           4                    16                    29               1             20     97                                                                       

  *ATM*                               CRC/N           5                    15                    30               0             25     100                                                                      

  *APC*                               CRC/N           4                    16                    30               0             20     100                                                                      

  *SFRP2*                             A/N             3                    22                    28               2             12     93                                                                       

  *MGMT*                              A/N             3                    22                    30               0             12     100                                                                      

  *MLH1*                              A/N             3                    22                    30               0             12     100                                                                      

  *HLTF*                              A/N             5                    20                    29               1             20     97                                                                       

  *ATM*                               A/N             4                    21                    30               0             16     100                                                                      

  *APC*                               A/N             4                    21                    30               0             16     100                                                                      

  *SFRP2*                             HP/N            1                    4                     28               2             20     93                                                                       

  *MGMT*                              HP/N            0                    5                     30               0             0      100                                                                      

  *MLH1*                              HP/N            1                    4                     30               0             20     100                                                                      

  *HLTF*                              HP/N            1                    4                     29               1             20     97                                                                       

  *ATM*                               HP/N            1                    4                     30               0             20     100                                                                      

  *APC*                               HP/N            0                    5                     30               0             0      100                                                                      

  Zhang, W., et al.\                  Germany         MSP                  CRC: 29\              *SFRP1*          CRC/N         24     5      15    2    83                                                     88
  (2007) \[[@pone.0200735.ref046]\]                                        A: 7\                                                                                                                                
                                                                           Control: 17                                                                                                                          

  *SFRP1*                             A/N             7                    0                     15               2             100    88                                                                       

  Chen, W.-D., et al.\                United States   MSP                  CRC: 94\              *VIM*            CRC/N         43     51     99    8    46                                                     92.5
  (2005) \[[@pone.0200735.ref047]\]                                        A: 50\                                                                                                                               
                                                                           HP: 29\                                                                                                                              
                                                                           Control: 107                                                                                                                         

  *VIM*                               A/N             6                    44                    99               8             12     92.5                                                                     

  *VIM*                               HP/N            6                    23                    99               8             21     92.5                                                                     

  Lenhard, K., et al.\                Germany         MSP                  CRC: 26\              *HIC1*           CRC/N         11     15     32    0    42                                                     100
  (2005) \[[@pone.0200735.ref048]\]                                        A: 13\                                                                                                                               
                                                                           HP: 9\                                                                                                                               
                                                                           Control: 32                                                                                                                          

  *HIC1*                              A/N             4                    9                     32               0             31     100                                                                      

  *HIC1*                              HP/N            0                    9                     32               0             0      100                                                                      

  Petko, Z., et al.\                  United States   MSP                  A: 28\                *MLH1*           A/N           0      28     17    2    0                                                      90
  (2005) \[[@pone.0200735.ref049]\]                                        HP: 10\                                                                                                                              
                                                                           Control: 19                                                                                                                          

  *MGMT*                              A/N             14                   14                    13               5             50     73                                                                       

  *CDKN2A (P16)*                      A/N             9                    18                    16               3             33     84                                                                       

  *MLH1*                              HP/N            0                    10                    17               2             0      90                                                                       

  *MGMT*                              HP/N            3                    7                     13               5             30     73                                                                       

  *CDKN2A (P16)*                      HP/N            1                    6                     16               3             14     84                                                                       

  Müller, H. M., et al.\              Austria         Methyl Light         CRC: 23\              *SFRP2*          CRC/N         19     4      20    6    83                                                     77
  (2004) \[[@pone.0200735.ref050]\]                                        Control: 26                                                                                                                          

  Leung, W. K., et al.\               China           MSP                  CRC: 20\              *ATM*            CRC/N         5      15     20    0    25                                                     100
  (2004) \[[@pone.0200735.ref051]\]                                        Control: 20                                                                                                                          

  *APC*                               CRC/N           4                    16                    20               0             20     100                                                                      

  *MGMT*                              CRC/N           4                    16                    20               0             20     100                                                                      

  *MLH1*                              CRC/N           4                    16                    20               0             20     100                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MSP: methylation specific PCR, qMSP: quantitative methylation specific PCR, MS-HRM: methylation specific-high resolution melting, MS-MCA: methylation specific- melting curve analysis, Hi-SA: high sequence assay. CRC: colorectal cancer, A: adenoma, AA: advanced- adenoma, NAA: non-advanced adenoma, HP: hyperplastic polyp, N: normal/control FN: false negative, the number of cancerous lesions with negative diagnoses, FP: false positive, the number of non-cancerous lesions with positive diagnoses, TN: true negative, the number of non-cancerous lesions with negative diagnoses, TP: true positive, the number of cancerous lesions with positive diagnoses.

\*Sensitivity (%) = TP/ (TP+FN) × 100% and specificity (%) = TN/ (TN+FP) × 100%.

Performance of single-gene stool DNA methylation biomarker tests {#sec011}
----------------------------------------------------------------

The results of the analysis of pooled sensitivity, specificity, PLR, NLR, and SROC of a stool-based DNA methylation biomarker test using all single-gene tests regardless of a specific gene in 3 categories (CRC, TA and TP) are shown in [Table 2](#pone.0200735.t002){ref-type="table"} and ([S1 File](#pone.0200735.s001){ref-type="supplementary-material"}). The results showed the performance of single-gene stool DNA methylation tests in CRC (DOR: 18.54; 95%CI, 15.25--22.54) is higher than the early stages of cancer, TA (DOR: 8.79; 95%CI, 6.07--12.71).

10.1371/journal.pone.0200735.t002

###### Performance of single-gene stool DNA methylation biomarker tests.

![](pone.0200735.t002){#pone.0200735.t002g}

  Groups    Sensitivity % (95%CI)   Specificity % (95%CI)   PLR (95%CI)              NLR (95%CI)              DOR (95%CI)                 AUC
  --------- ----------------------- ----------------------- ------------------------ ------------------------ --------------------------- --------
  **CRC**   56.5 \[55--58\]         93 \[92--94\]           6.438 \[5.629--7.362\]   0.496 \[0.448--0.549\]   18.541 \[15.250--22.542\]   0.9033
  **TA**    33 \[30--35\]           93 \[92--94\]           4.903 \[3.858--6.232\]   0.726 \[0.669--0.788\]   8.787 \[6.073--12.714\]     0.8838
  **TP**    50 \[48--51\]           93 \[92--94\]           5.977 \[5.151--6.934\]   0.547 \[0.500--0.598\]   14.392 \[11.720--17.673\]   0.8814

CRC: colorectal cancer, TA: total adenoma TP: total patients, PLR: positive likelihood ratio, NLR: negative likelihood ratio, DOR: diagnosis odd ratio, AUC: area under the ROC curve

Performance of a certain gene in single-gene stool-based DNA methylation biomarker tests {#sec012}
----------------------------------------------------------------------------------------

We pooled estimates for sensitivity, specificity, PLR, NLR, DOR and the SROC of a stool-based DNA methylation biomarker test using all single-gene tests considering a certain gene in our 5 categories including CRC, AA, NAA, HP, TA, TP. The results of the analysis of pooled data from all genes which have been reported at least in three studies are shown in [Table 3](#pone.0200735.t003){ref-type="table"} and ([S2 File](#pone.0200735.s002){ref-type="supplementary-material"}). The results elucidated that Secreted Frizzled-Related Protein 1 (*SFRP1)* and Secreted Frizzled-Related Protein 2 (*SFRP2)* methylation possess the highest accuracy for detection of not only CRC (DOR: 31.67; 95%CI, 12.31--81.49 and DOR: 35.36; 95%CI, 18.71--66.84, respectively) but also the early stages of cancer, TA (DOR: 19.72; 95%CI, 6.68--58.25 and DOR: 13.20; 95%CI, 6.01--28.00, respectively) as illustrated in [Fig 2](#pone.0200735.g002){ref-type="fig"}. N-myc downstream regulated gene 4 (*NDRG4)* could be also considered as a significant diagnostic marker gene in CRC (DOR: 24.37; 95%CI, 10.11--58.73) and Vimentin (*VIM*) in adenoma (DOR: 15.21; 95%CI, 2.72--85.10).

![Summary estimates of SFRP1 and SFRP2.\
(A) Summary estimates of SFRP1. hypermethylation in stool samples used for TP (CRC+ Adenoma) diagnosis. Red circles represent each study that was included in the meta-analysis. The size of each study is indicated by the size of the red circle. Error bars indicate the 95% confidence interval (CI). Positive LR: positive likelihood ratio, Negative LR: negative likelihood ratio, Diagnostic OR: diagnosis odd ratio, SROC curves: summary receiver operating characteristic curve. (B) Summary estimates of SFRP2. hypermethylation in stool samples used for TP (CRC+ Adenoma) diagnosis. Red circles represent each study that was included in the meta-analysis. The size of each study is indicated by the size of the red circle. Error bars indicate the 95% confidence interval (CI). Positive LR: positive likelihood ratio, Negative LR: negative likelihood ratio, Diagnostic OR: diagnosis odd ratio, SROC curves: summary receiver operating characteristic.](pone.0200735.g002){#pone.0200735.g002}

10.1371/journal.pone.0200735.t003

###### Performance of a certain gene in all single-gene stool-based DNA methylation biomarker tests included in this meta- analysis.

![](pone.0200735.t003){#pone.0200735.t003g}

  GENES     Number of studies   Sensitivity\* % (95%CI)   Specificity\* % (95%CI)   PLR (95%CI)                NLR (95%CI)               DOR (95%CI)                 AUC
  --------- ------------------- ------------------------- ------------------------- -------------------------- ------------------------- --------------------------- --------
  **CRC**                                                                                                                                                            
  *SFRP2*   12                  74.5 \[71--78\]           93 \[90--95 \]            7.917 \[5.415--11.576\]    0.294 \[0.205--0.422\]    35.362 \[18.709--66.839\]   0.9436
  *VIM*     8                   52 \[47--57\]             88 \[85--90\]             4.899 \[3.932--6.104\]     0.523 \[0.424--0.644\]    12.056 \[7.885--18.432\]    0.8686
  *MGMT*    5                   41 \[33--48\]             96 \[91--99\]             5.336 \[2.576--11.054\]    0.674 \[0.563--0.807\]    9.797 \[4.127--23.258\]     0.7234
  *MLH1*    3                   26 \[18--36\]             100 \[96--100\]           14.154 \[2.755--72.724\]   0.754 \[0.671--0.848\]    18.613 \[3.415--101.45\]    0.5653
  *HLTF*    3                   71 \[52--85\]             74 \[68--80\]             2.567 \[1.835--3.590\]     0.427 \[0.261--0.699\]    7.890 \[3.444--18.074\]     0.8094
  *SFRP1*   4                   73.5 \[64--81\]           92 \[84--97\]             7.938 \[3.775--16.689\]    0.301 \[0.156--0.578\]    31.670 \[12.307--81.495\]   0.9437
  *APC*     3                   25 \[15--37\]             100 \[94--100\]           10.771 \[2.097--55.317\]   0.771 \[0.671--0.887\]    14.13 \[2.55--78.27\]       0.8565
  *P16*     3                   31 \[21--41\]             98 \[92--100\]            10.409 \[2.566--42.218\]   0.731 \[0.626--0.852\]    15.056 \[3.409--66.498\]    0.9639
  *NDRG4*   3                   57 \[50--64\]             95 \[90--98\]             10.027 \[4.585--21.929\]   0.464 \[0.269--0.802\]    24.374 \[10.115--58.730\]   0.9061
  **AA**                                                                                                                                                             
  *SFRP2*   5                   56 \[47--64\]             93 \[90--96\]             6.592 \[3.941--11.024\]    0.486 \[0.374--0.632\]    14.379 \[6.873--30.083\]    0.8912
  *VIM*     3                   73 \[60--83\]             85 \[81--89\]             7.722 \[2.519--23.671\]    0.269 \[0.073--0.990\]    38.881 \[14.523--104.09\]   0.9549
  **NAA**                                                                                                                                                            
  *SFRP2*   3                   34 \[23--48\]             94 \[89--97\]             5.422 \[1.849--15.900\]    0.710 \[0.595--0.847\]    7.915 \[2.328--26.906\]     0.0438
  **HP**                                                                                                                                                             
  *SFRP2*   7                   30 \[22--40\]             94 \[90--97\]             6.116 \[3.370--11.099\]    0.740 \[0.617--0.888\]    9.488 \[4.368--20.608\]     0.8646
  *MGMT*    3                   22 \[6--48\]              88 \[74--96\]             1.803 \[0.310--10.476\]    0.880 \[0.682--1.136\]    2.046 \[0.302--13.868\]     \-
  **TA**                                                                                                                                                             
  *SFRP2*   8                   45 \[39--51\]             94 \[91--96\]             6.905 \[3.767--12.657\]    0.575 \[0.447--0.738\]    13.200 \[6.009--28.996\]    0.8882
  *VIM*     5                   36 \[29--44\]             88 \[85--90\]             5.466 \[2.689--11.112\]    0.571 \[0.350--0.932\]    15.211 \[2.719--85.105\]    0.9470
  *MGMT*    5                   28 \[21--35\]             92 \[86--96\]             2.507 \[1.417--4.438\]     0.823 \[0.712--0.951\]    3.829 \[1.811--8.097\]      0.6224
  *MLH1*    3                   82 \[48--98\]             47 \[39--54\]             1.682 \[0.954--2.964\]     0.467 \[0.012--17.634\]   2.380 \[0.140--40.403\]     0.4167
  *SFRP1*   3                   59 \[45--71\]             92 \[83--97\]             6.754 \[3.297--13.837\]    0.451 \[0.190--1.074\]    19.720 \[6.676--58.253\]    0.9221
  *P16*     3                   24 \[16--35\]             94 \[85--98\]             3.124 \[1.203--8.114\]     0.815 \[0.715--0.928\]    4.303 \[1.393--13.291\]     0.4720
  **TP**                                                                                                                                                             
  *SFRP2*   12                  66 \[63--69\]             93 \[92--95\]             8.121 \[5.316--12.407\]    0.370 \[0.271--0.504\]    26.317 \[14.200--48.773\]   0.9128
  *VIM*     8                   47 \[43--51\]             88 \[86--90\]             5.236 \[3.915--7.003\]     0.509 \[0.389--0.665\]    12.636 \[7.216--22.128\]    0.8695
  *MGMT*    6                   34 \[30--40\]             94 \[90--97\]             4.859 \[1.914--12.331\]    0.733 \[0.633--0.850\]    6.984 \[2.890--16.877\]     0.6091
  *MLH1*    4                   17 \[12--23\]             99 \[96--100\]            5.530 \[0.502--60.878\]    0.877 \[0.754--1.021\]    6.353 \[0.504--80.138\]     0.3237
  *HLTF*    4                   28 \[19--37\]             95 \[90--97\]             5.464 \[2.857--10.447\]    0.771 \[0.677--0.879\]    7.808 \[3.592--16.973\]     0.7726
  *SFRP1*   4                   68 \[61--75\]             92 \[86--96\]             7.786 \[4.563--13.286\]    0.349 \[0.191--0.637\]    30.237 \[14.850--61.567\]   0.9264
  *APC*     3                   24 \[16--32\]             100 \[97--100\]           15.551 \[3.053--79.207\]   0.782 \[0.710--0.861\]    20.137 \[3.764--107.73\]    0.6715
  *P16*     4                   27.5 \[21--35\]           96 \[91--99\]             5.331 \[1.888--15.052\]    0.761 \[0.692--0.839\]    7.330 \[2.759--19.476\]     0.4028
  *NDRG4*   3                   57 \[50--64\]             95 \[90--93\]             10.027 \[4.585--21.929\]   0.464 \[0.269--0.802\]    24.374 \[10.115--58.730\]   0.9061

CRC: colorectal cancer, AA: advanced- adenoma, NAA: non-advanced adenoma, HP: hyperplastic polyp, TA: total adenoma TP: total patients, PLR: positive likelihood ratio, NLR: negative likelihood ratio, DOR: diagnosis odd ratio, AUC: area under the ROC curve

Publication bias {#sec013}
----------------

In our meta-analysis, publication bias was evaluated using Egger Test, a test for asymmetry of the funnel plot. The statistical results of Deek's funnel plot did not show any obvious asymmetry and publication bias for all single-gene tests regardless of a specific gene in CRC (p-value = 0.904), TA (p-value = 0.486) and TP (p-value = 0.376) ([Fig 3](#pone.0200735.g003){ref-type="fig"}).

![Publication bias of studies in different categories.\
CRC: colorectal cancer, TA: total adenoma, TP: total patients.](pone.0200735.g003){#pone.0200735.g003}

Quality assessment {#sec014}
------------------

Quality assessment of the different studies found the greatest potential risk of bias, which came from patient selection, as most of the studies did not collect a consecutive or random sample ([S2 Table](#pone.0200735.s005){ref-type="supplementary-material"} and [S3 File](#pone.0200735.s003){ref-type="supplementary-material"}).

Discussion {#sec015}
==========

In the present study, we evaluated the clinical value of DNA hypermethylation of different genes as biomarkers for the diagnosis of CRC. Based on the pooled FP, FN, TP and TN of different methylated genes and considering the pooled sensitivity, specificity, PLR, NLR, DOR and SROC in different categories of CRC, the most diagnostic candidate genes were identified.

It is worth noting that a substantial heterogeneity and imprecision existed among the included studies was not due to non-standard or false identification/diagnosis of CRC and gene methylation. This was also reflected numerically as Q test and the I^2^ statistic which showed that the majority of analyses were not subjected to high heterogeneity ([S4 File](#pone.0200735.s007){ref-type="supplementary-material"}). While heterogeneity was inherent to any type of meta-analysis, the numerous analyses performed in the current study could reflect an authentic association.

The most advantage of this meta-analysis is the accuracy assessment of hypermethylated genes, which was calculated for each gene separately in the process of CRC (hyperplastic polyp, non-advanced adenoma, advanced adenoma, cancer tumor).

Based on our results, we concluded a methylation cascade of candidate genes in the process of colorectal cancer. The results demonstrated that *SFRP2*, *SFRP1* and *NDRG4* in CRC; *VIM* in AA; *SFRP1*, *VIM* and *SFRP2* in TA; *SFRP2* in HP; and *SFRP1*, *SFRP2*, *NDRG4* and *VIM* in TP patients offer the most accurate detection in their corresponding categories ([Fig 4](#pone.0200735.g004){ref-type="fig"}).

![Methylation of candidate genes in different categories.\
Different genes are hypermethylated in development of CRC. CRC: colorectal cancer, AA: advanced-adenoma, NAA: non-advanced adenoma.](pone.0200735.g004){#pone.0200735.g004}

Zhang and his colleagues in their meta-analysis showed that *SFRP2* methylation serves as a promising marker with a great potential in early colorectal cancer diagnosis \[[@pone.0200735.ref052]\]. [Fig 4](#pone.0200735.g004){ref-type="fig"} displays the methylated candidate genes in developing CRC. *SFRP1/ SFRP2* genes encode a member of the SFRP family that encodes soluble modulators of Wnt signaling. Epigenetic silencing of SFRP genes leads to downregulated activation of the Wnt-pathway which is often silenced by promoter hypermethylation in CRC \[[@pone.0200735.ref006], [@pone.0200735.ref053], [@pone.0200735.ref054]\]. *NDRG4* is a member of the NDRG family that includes a group of genes that have mostly tumor-suppressive effects. This novel candidate tumor suppressor gene, associated with energy balance and carcinogenesis, can inhibit PI3K/AKT signaling and controls cell growth and differentiation. *NDRG4* is downregulated by methylation in CRC \[[@pone.0200735.ref006], [@pone.0200735.ref053], [@pone.0200735.ref055]\]. The role of *NDRG4* as a tumor suppressor gene was demonstrated first by Melotte et al. They studied the *NDRG4* promoter methylation in the lines of colorectal cancerous cells, colorectal tissue and healthy colonic mucosa \[[@pone.0200735.ref034]\]. In August 2014, Cologuard^TM^ (Exact Sciences, Madison, WI, USA), a stool DNA test was approved by US FDA, based on molecular testing for the aberrant methylated regions of the promoters *NDRG4* and *BMP3*, muted *KRAS* and *β-actin* and an immunochemical test for human hemoglobin \[[@pone.0200735.ref004]\]. *VIM* is an intermediate filament protein and could increase the mechanical cell integrity and localize intracellular components. Aberrantly methylated *VIM* was already a diagnostic marker for early detection of CRC in the United States \[[@pone.0200735.ref006], [@pone.0200735.ref053], [@pone.0200735.ref056]\]. Hence, all candidate genes play important roles in the carcinogenesis of CRC.

Fecal immunochemical tests (FITs) and g-FOBTs are most commonly used in CRC screening programs. The sensitivity (specificity) of g-FOBT and FIT in cancer patients was 74.2% (95.7%) and 87.1% (91%), respectively, and in patients with AA, the sensitivity (specificity) of g-FOBT and FIT was 18.0% (97.4%) and 35.6% (97.2%), respectively \[[@pone.0200735.ref057]\]. Since the sensitivity is low for screening tests in both methods, researchers are seeking for other screening programs.

Methylated DNA is an attractive choice to serve as a biomarker substrate because CRCs harbor hundreds of aberrantly methylated genes \[[@pone.0200735.ref006]\]. Methylated DNA biomarkers can be detected in serum/plasma and stool of CRC patients \[[@pone.0200735.ref008], [@pone.0200735.ref058], [@pone.0200735.ref059]\]. Li et al. conducted a meta-analysis of DNA hypermethylation markers in peripheral blood for CRC detection. They found that single target gene had a sensitivity of 60% and a specificity of 94.3% for CRC detection \[[@pone.0200735.ref058]\]. A large number of studies verified the efficacy of detecting methylated DNA in stool to screen for early CRC and there are several meta-analyses assessing the diagnostic value of stool DNA testing \[[@pone.0200735.ref052], [@pone.0200735.ref060]--[@pone.0200735.ref062]\]. Zhai et al. reported the pooled sensitivities for single- and multiple-gene stool DNA (methylation and mutation) tests in CRC to be 48.0% and 77.8%, and the pooled specificity for single- and multiple-gene assays to be 97.0% and 92.7%, respectively \[[@pone.0200735.ref062]\]. Zhang and colleagues reported a sensitivity and specificity of combined single- and multiple-gene methylation analysis of stool DNA samples in CRC to be 73% and 92%, and for adenoma to be 51% and 92%, respectively \[[@pone.0200735.ref052]\]. In another study for methylated single- and multiple-gene tests in fecal samples, Luo et al. demonstrated an overall sensitivity of 62% and 54%, and a specificity of 89% and 88% in CRC and adenoma patients, respectively \[[@pone.0200735.ref060]\]. In the Qian et al., meta-analysis, the pooled sensitivity of the combined single- and multiple-gene DNA hypermethylation in stool was 71% and its specificity was 92% for CRC \[[@pone.0200735.ref061]\]. In the current study, single-gene stool DNA methylation analysis had a sensitivity (specificity) for CRC and adenoma of 56.5% (93.2%) and 32.6% (93.2%), respectively. These statistics demonstrated a lower sensitivity and specificity in compare to previous studies. Overall, there is a stool single-gene DNA methylation performance of 49.8% sensitivity and 92.9% specificity in diagnosis of CRC developing process in our study.

The difference in reported specificity and sensitivity among meta-analysis studies may reflect differences in included studies and their studied population. In our meta-analysis, fewer Chinese-based studies were included and single-gene stool DNA methylation tests were specifically considered. Individual study quality was assessed by QUADAS-2 tool to assess the quality of primary diagnostic accuracy studies. The quality assessment for all included studies revealed that there was a low risk of bias in all domains except in patient selection which was inevitable. As they were case-control studies they had similar criteria in their patient selection domain.

The current meta-analysis had several limitations which were considered when interpreting our results: (1) most publications included in the analysis were case-control studies and none of the included studies was a multicenter or randomized controlled trial, (2) in any meta-analysis, the effect of languages selection bias cannot be ignored, (3) studies on DNA methylation with statistical significance tend to be published and cited, (4) we excluded some of the valuable multi-gene studies from our meta-analysis due to the absence of sufficient data for each gene separately, and (5) the included studies did not account for the effect of sex, lifestyle, aging, diet and methodology on their findings.

In conclusion, our results demonstrated that *SFRP1* and *SFRP2* methylation assays, as non-invasive modalities, have promising accuracy for the detection of not only CRC but also the early stages of developing colorectal cancer. Besides, *NDRG4* and *VIM* could also be considered as significant diagnostic marker genes in CRC and adenoma, respectively.

Hence, this meta- analysis could be a helpful source for scientists to compare the diagnostic performance and accuracy of hypermethylated genes and could provide valuable insights into design for further proof-of-concept studies. Although in our meta-analysis each gene was calculated separately in the process of colorectal cancer, the results could be used for singular or combined, multi-marker assays.
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